Court Ruling Finds that ERISA Preempts State PBM Law COURT REJECTS BID TO PREEMPT ERISA…In a unanimous decision, the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready court sustained PCMA’s challenge to four provisions in
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
(Washington, D.C.) — As employers confront a challenging economic environment and are examining options to both reduce costs and improve health care quality for workers, a national survey of benefit managers and human resources directors from North Star Opinion Research
Main Information On Tadalafil Principle of Action Tadalafil is the main active ingredient of Cialis, one of the most popular drugs for erectile dysfunction (ED) today. This substance is responsible for the effect of Cialis on the male body. How
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act will increase taxpayer spending by approximately $23 billion over 10 years. Pharmacy benefit managers, PBMs,
New report from the Congressional Budget Office highlights the value of PBMs in keeping net drug costs low for payers and patients.
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Energy and Commerce Committee’s inclusion of full repeal of the rebate rule in the committee’s legislative recommendations for its budget reconciliation bill
©2024 PCMA. All Rights Reserved.
